

References

- Aldossary, S. A. (2019). Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. *Biomedical and Pharmacology Journal*, 12(1), 7-15.
- Amatori, S., Persico, G., & Fanelli, M. (2017). Real-time quantitative PCR array to study drug-induced changes of gene expression in tumor cell lines. *J. Cancer Metastasis Treat*, 3, 90.
- Astolfi, L., Ghiselli, S., Guaran, V., Chicca, M., Simoni, E., Olivetto, E., ... & Martini, A. (2013). Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. *Oncology reports*, 29(4), 1285-1292.
- Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018). How does *p53* induce apoptosis and how does this relate to *p53*-mediated tumour suppression?. *Cell Death & Differentiation*, 25(1), 104-113.
- Bagalkotkar, G., Sagineedu, S. R., Saad, M. S., & Stanslas, J. (2006). Phytochemicals from *Phyllanthus niruri* Linn. and their pharmacological properties: a review. *Journal of pharmacy and pharmacology*, 58(12), 1559-1570.
- Basu, A., & Krishnamurthy, S. (2010). Cellular responses to Cisplatin-induced DNA damage. *Journal of nucleic acids*, 2010.
- Carpenter, R., & Brady, M. F. (2020). *BAX* gene.
- Du, W., & Searle, J. S. (2009). The *rb* pathway and cancer therapeutics. *Current drug targets*, 10(7), 581-589.
- Elmore, S. (2007). Apoptosis: a review of programmed cell death. *Toxicologic pathology*, 35(4), 495-516.
- Giacinti, C., & Giordano, A. (2006). *RB* and cell cycle progression. *Oncogene*, 25(38), 5220-5227.
- Harikumar, K. B., Kuttan, G., & Kuttan, R. (2009). *Phyllanthus amarus* inhibits cell growth and induces apoptosis in Dalton's lymphoma ascites cells through activation of caspase-3 and downregulation of *Bcl-2*. *Integrative cancer therapies*, 8(2), 190-194.
- Harris, S. L., & Levine, A. J. (2005). The *p53* pathway: positive and negative feedback loops. *Oncogene*, 24(17), 2899-2908.
- Hemann, M. T., & Lowe, S. W. (2006). The *p53*-*bcl-2* connection. *Cell death and differentiation*, 13(8), 1256.
- Huang, C. Y., Ju, D. T., Chang, C. F., Reddy, P. M., & Velmurugan, B. K. (2017). A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. *Biomedicine*, 7(4).
- Issaeva, N. (2019). *p53* signaling in cancers.
- Jeng, P. S., Inoue-Yamauchi, A., Hsieh, J. J., & Cheng, E. H. (2018). BH3-dependent and independent activation of *BAX* and *BAK* in mitochondrial apoptosis. *Current opinion in physiology*, 3, 71-81.
- Joerger, A. C., & Fersht, A. R. (2016). The *p53* pathway: origins, inactivation in cancer, and emerging therapeutic approaches. *Annual review of biochemistry*, 85, 375-404.
- Kuang, J., Yan, X., Genders, A. J., Granata, C., & Bishop, D. J. (2018). An overview of technical considerations when using quantitative real-time PCR analysis of gene expression in human exercise research. *PLoS one*, 13(5), e0196438.
- Lee, N. Y., Khoo, W. K., Adnan, M. A., Mahalingam, T. P., Fernandez, A. R., & Jeevaratnam, K. (2016). The pharmacological potential of *Phyllanthus niruri*. *Journal of pharmacy and pharmacology*, 68(8), 953-969.
- Li, M. (2021). The role of *P53* up-regulated modulator of apoptosis (*PUMA*) in ovarian development, cardiovascular and neurodegenerative diseases. *Apoptosis*, 1-13.
- Lomonosova, E., & Chinnadurai, G. (2008). BH3-only proteins in apoptosis and beyond: an overview. *Oncogene*, 27(1), S2-S19.
- Lucey, B. P., Nelson-Rees, W. A., & Hutchins, G. M. (2009). Henrietta Lacks, HeLa cells, and cell culture contamination. *Archives of pathology & laboratory medicine*, 133(9), 1463-1467.

- Lyapun, I. N., Andryukov, B. G., & Bynina, M. P. (2019). HeLa Cell Culture: Immortal Heritage of Henrietta Lacks. *Molecular Genetics, Microbiology and Virology*, *34*, 195-200.
- Makovec, T. (2019). Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. *Radiology and oncology*, *53*(2), 148-158.
- Masters, J. R. (2002). HeLa cells 50 years on: the good, the *Bad* and the ugly. *Nature Reviews Cancer*, *2*(4), 315-319.
- Maximov, G. K., & Maximov, K. G. (2008). The role of *p53* tumor-suppressor protein in apoptosis and cancerogenesis. *Biotechnology & Biotechnological Equipment*, *22*(2), 664-668.
- Mirabelli, P., Coppola, L., & Salvatore, M. (2019). Cancer cell lines are useful model systems for medical research. *Cancers*, *11*(8), 1098.
- Nguyen, V. T., Sakoff, J. A., & Scarlett, C. J. (2017). Physicochemical properties, antioxidant and cytotoxic activities of crude extracts and fractions from *Phyllanthus amarus*. *Medicines*, *4*(2), 42.
- Nisar, M. F., He, J., Ahmed, A., Yang, Y., Li, M., & Wan, C. (2018). Chemical components and biological activities of the genus *phyllanthus*: A review of the recent literature. *Molecules*, *23*(10), 2567.
- Oren, M., & Rotter, V. (2010). Mutant *p53* gain-of-function in cancer. *Cold Spring Harbor perspectives in biology*, *2*(2), a001107.
- Panina, Y., Germond, A., Masui, S., & Watanabe, T. M. (2018). Validation of common housekeeping genes as reference for qPCR gene expression analysis during iPS reprogramming process. *Scientific reports*, *8*(1), 1-8.
- Prabhakaran, P., Hassiotou, F., Blancafort, P., & Filgueira, L. (2013). Cisplatin induces differentiation of breast cancer cells. *Frontiers in oncology*, *3*, 134.
- Puspita, N. A., & Alhebshi, H. (2019). The effect of *Phyllanthus niruri* L extracts on human leukemic cell proliferation and apoptosis induction. *Indonesian Journal of Pharmacy*, *30*(4).
- Qian, B., Zhao, L. J., Teng, F., Gao, L. J., & Shen, R. (2018). Role of the tumour protein *P53* gene in human cervical squamous carcinoma cells: Discussing haematopoietic cell-specific protein 1-associated protein X-1-induced survival, migration and proliferation. *Oncology letters*, *16*(2), 2629-2637.
- Sayuti, M., Riwanto, I., Boediono, B. P., & Akbar, T. I. S. (2020). Anticancer Activity of *Phyllanthus Niruri* Linn Extract in Colorectal Cancer Patients: A phase II Clinical Trial. *Studies*, *10*, 17.
- Silver, N., Best, S., Jiang, J., & Thein, S. L. (2006). Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. *BMC molecular biology*, *7*(1), 33.
- Sionov, R. V., Hayon, I. L., & Haupt, Y. (2013). The regulation of *p53* growth suppression. In *Madame Curie Bioscience Database [Internet]*. Landes Bioscience.
- Sordo-Bahamonde, C., Lorenzo-Herrero, S., Payer, Á. R., Gonzalez, S., & López-Soto, A. (2020). Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer. *International journal of molecular sciences*, *21*(10), 3726.
- Tang, Y. Q., Jaganath, I. B., & Sekaran, S. D. (2010). *Phyllanthus* spp. induces selective growth inhibition of PC-3 and MeWo human cancer cells through modulation of cell cycle and induction of apoptosis. *PloS one*, *5*(9), e12644.
- Tang, Y. Q., & Sekaran, S. D. (2011). Evaluation of *Phyllanthus* for its anti-cancer properties. *Prostate cancer-from bench to bedside*, 305-320.
- Toufektchan, E., & Toledo, F. (2018). The guardian of the genome revisited: *p53* downregulates genes required for telomere maintenance, DNA repair, and centromere structure. *Cancers*, *10*(5), 135.
- Tzifi, F., Economopoulou, C., Gourgiotis, D., Ardavanis, A., Papageorgiou, S., & Scorilas, A. (2012). The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. *Advances in hematology*, 2012.
- Vélez-Cruz, R., & Johnson, D. G. (2017). The retinoblastoma (RB) tumor suppressor: pushing back against genome instability on multiple fronts. *International journal of molecular sciences*, *18*(8), 1776.

- Velotti, F., Barchetta, I., Cimini, F. A., & Cavallo, M. G. (2020). Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. *Frontiers in immunology*, *11*, 2828.
- Warren, C. F., Wong-Brown, M. W., & Bowden, N. A. (2019). BCL-2 family isoforms in apoptosis and cancer. *Cell death & disease*, *10*(3), 1-12.
- Westphal, D., Kluck, R. M., & Dewson, G. (2014). Building blocks of the apoptotic pore: how *BAX* and *Bak* are activated and oligomerize during apoptosis. *Cell Death & Differentiation*, *21*(2), 196-205.
- Yin, C., Li, J., He, Q., Liu, S., & He, L. (2017). Mutations and reduced expression of *p53* gene are involved in HPV-independent oncogenesis of cervical cancer. *INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY*, *10*(4), 4356-4362.
- Zhang, H., & Chen, J. (2018). Current status and future directions of cancer immunotherapy. *Journal of Cancer*, *9*(10), 1773.
- Zheng, Z. Z., Chen, L. H., Liu, S. S., Deng, Y., Zheng, G. H., Gu, Y., & Ming, Y. L. (2016). Bioguided Fraction and Isolation of the Antitumor Components from *Phyllanthus niruri* L. *BioMed research international*, 2016.